Ozempic, a medication developed by Novo Nordisk, is used to improve glycemic control in adults with type 2 diabetes. It contains the active ingredient semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 receptor agonists work by mimicking the functions of natural hormones in the body to regulate blood sugar levels.

According to the drug's prescribing information, Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

It is important to note that while Ozempic can help manage blood sugar levels, it is not a cure for type 2 diabetes. Proper diet, exercise, and regular monitoring of blood sugar levels are still essential for effective diabetes management.

Sources:

* Novo Nordisk. (2021). Ozempic (semaglutide) injection. Retrieved from <https://www.novo-pi.com/ozempic.pdf>
* DrugPatentWatch. (2021). Ozempic (semaglutide) drug patent insights. Retrieved from <https://www.drugpatentwatch.com/drugs/ozempic>